Interesting that they are now reflecting Lantheus' view of the market size for prostate imaging as >US3b
I agree that >US2b is well and truly feasible for market share in the next 2 years across the three imaging products. For me the trajectory of the company is clear: in two years the imaging builds up momentum and then at that time the therapy trials should start yielding results.
Ann: Telix 1H 2024 Results Presentation, page-6
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.73 |
Change
0.290(1.42%) |
Mkt cap ! $6.937B | |||
| Open | High | Low | Value | Volume |
| $20.57 | $20.73 | $20.16 | $20.61M | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 74 | $20.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.75 | 12799 | 5 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| TLX (ASX) Chart |